The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.
Michael Grabner, PhD
Advertisement
Articles by Michael Grabner, PhD
Advertisement
Latest Updated Articles
- Racial Variation in the Cost-effectiveness of Chemotherapy for Prostate Cancer
Published: May 18th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
4
Myasthenia Gravis–Induced Fears of Diagnosed Patients During the Pandemic
5
